HEcoPerMed, personalized medicine from a health economic perspective: lessons learned and potential opportunities ahead
M Rutten-van Mölken, M Versteegh, B Nagy… - Personalized …, 2023 - Taylor & Francis
We are pleased to introduce this special issue of Personalized Medicine, presenting the
main findings and lessons learned from the Healthcare and Pharma-economics in Support …
main findings and lessons learned from the Healthcare and Pharma-economics in Support …
Budget impact and transferability of cost–effectiveness of DPYD testing in metastatic breast cancer in three health systems
R Koleva-Kolarova, H Vellekoop, S Huygens… - Personalized …, 2023 - Taylor & Francis
The cost–effectiveness and budget impact of introducing extended DPYD testing prior to
fluoropyrimidine-based chemotherapy in metastatic breast cancer patients in the UK, The …
fluoropyrimidine-based chemotherapy in metastatic breast cancer patients in the UK, The …
Lessons learned from the application of the HEcoPerMed guidance to three modeling case studies
B Nagy, T Zelei, H Vellekoop, S Huygens… - Personalized …, 2023 - Taylor & Francis
Background: The HEcoPerMed consortium developed a methodological guidance for the
harmonization and improvement of economic evaluations in personalized medicine …
harmonization and improvement of economic evaluations in personalized medicine …
Looking back over 2023 and welcome to the 21st issue of Personalized Medicine
S Jones - Personalized Medicine, 2024 - Taylor & Francis
Conclusion As with the previous years, we are open to all feedback from the personalized
and precision medicine communities regarding the direction of our journal's content …
and precision medicine communities regarding the direction of our journal's content …